Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
With a market cap of 81.85B, Regeneron(REGN) trades at $774.66. The stock has a price-to-earnings ratio of 18.61 and currently yields dividends of 46.4%.
On 2026-03-11, Regeneron(REGN) stock traded between a low of $765.00 and a high of $783.12. Shares are currently priced at $774.66, which is +1.3% above the low and -1.1% below the high.
The Regeneron(REGN)'s current trading volume is 383.35K, compared to an average daily volume of 636.65K.
During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.
During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.
REGN News
Andrew Leyden/Getty Images The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50...
Earlier this month, Regeneron Pharmaceuticals and partner Hansoh Pharma reported positive Phase 3 results in Chinese patients for olatorepatide, a dual GLP-1/GI...
(RTTNews) - Regeneron Pharmaceuticals said olatorepatide, an investigational obesity treatment it licensed from Hansoh Pharmaceutical Group, delivered positive...
Analyst ratings
73%
of 30 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN) said its partner Hansoh Pharma reported positive Phase 3 results for obesity drug olatorepatide in Chinese patients. The once-...
Regeneron Pharmaceuticals (REGN) announced Hansoh Pharmaceutical Group Company (HNSPF) has shared topline data from its Phase 3 trial in Chinese patients evalua...
Advertisement Regeneron Pharmaceuticals overview Regeneron Pharmaceuticals (REGN) has drawn investor attention after its shares closed at US$764.93, with rece...
Barclays initiated coverage of Regeneron (REGN) with an Overweight rating and $923 price target The shares are “fundamentally mispricing” the company’s profits...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.